Clinical And Economic Implications Of Crestor JUPITER Study Headline ACC Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Planet-struck American College of Cardiology kicks off its annual scientific session with a focus on the impact of AstraZeneca’s high-profile rosuvastatin study for medical practice and for the economics of cardiac health care.
You may also be interested in...
Crestor Gets Advisory Committee For Preventing Cardiovascular Events
If AstraZeneca gets JUPITER results on label, it could improve reimbursement for the indication in patients with healthy cholesterol levels but biomarker for inflammation and at least one CVD risk factor.
Crestor Gets Advisory Committee For Preventing Cardiovascular Events
If AstraZeneca gets JUPITER results on label, it could improve reimbursement for the indication in patients with healthy cholesterol levels but biomarker for inflammation and at least one CVD risk factor.
JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting